The UK Court of Appeals has affirmed the validity of Moderna's EP'949 patent covering modified mRNA in COVID-19 vaccines, ruling that Pfizer and BioNTech infringed on this intellectual property. This decision bolsters Moderna's patent portfolio and supports ongoing global enforcement efforts. It confirms prior rulings regarding mRNA modifications that enhance vaccine stability and immune activation, affecting commercial dynamics in the mRNA vaccine market.